News
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), March 17, 2023: SkylineDx, an innovative diagnostics company, focused on research & development of molecular diagnostics for oncology and inflammatory diseases, today announced the publication of...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), September 1, 2022: Today, SkylineDx, a leading molecular diagnostics company, announces the commercial launch of Merlin Assay as CE-IVD distributable test kit in Europe. Merlin Assay...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), May 25, 2022: Today, SkylineDx, a leading molecular diagnostics company, announces Medicare coverage for Merlin Test. The local coverage determination was issued under the foundational policy...
ROTTERDAM (the Netherlands), SAN DIEGO (USA), April 26, 2022: Today, SkylineDx, a leading molecular diagnostics company, announced the addition of new leadership to reinforce their commitment to bringing personalized diagnostics to the...
ROTTERDAM (the Netherlands), SAN DIEGO (USA), April 21, 2022: Today, SkylineDx presents new data showing that their Merlin Test was able to prospectively reduce >37% of surgeries in a non-interventional study for newly...
ROTTERDAM (the Netherlands), SAN DIEGO (USA), February 24, 2022: today, SkylineDx announced that their Merlin Test for melanoma patients would have been able to reduce over 59% of surgery-related complications by means of...
ROTTERDAM (the Netherlands), SAN DIEGO (US), GHENT (Belgium), December 22, 2021: Today, SkylineDx announced a 3-year strategic partnership with life sciences institute VIB for the evaluation and initiation of collaborative projects focused on...
ROTTERDAM (the Netherlands), SAN DIEGO (USA), December 21, 2021: today, SkylineDx announced it received a capital investment from USA based investment and advisory firm Novalis LifeSciences, and one of Benelux’ largest biotech investors...
ROTTERDAM (the Netherlands), SAN DIEGO (California, US), November 9, 2021: today, SkylineDx announced that the Accreditation Committee of the College of American Pathologists (CAP) has renewed accreditation to SkylineDx’ laboratory in San Diego, California...
ROTTERDAM (the Netherlands), SAN DIEGO (US), October 12, 2021: today, SkylineDx announced it has entered into an exclusive patent license agreement with Imperial College London for the worldwide development and commercialization of a...
ROTTERDAM (the Netherlands), SAN DIEGO (US), June 24, 2021: Today, SkylineDx announced to invest in research and development in the field of Squamous Cell Carcinoma (SCC), as part of a Dutch consortium including...
ROTTERDAM (the Netherlands), SAN DIEGO (US), June 10, 2021: Today, SkylineDx announced that the first hospitals will start including melanoma patients in a large prospective clinical study in the United States, to validate...
ROTTERDAM (the Netherlands), SAN DIEGO (US), April 30, 2021: SkylineDx announced that the performance of their melanoma diagnostic test (Merlin Assay) is confirmed in an independent group of U.S. patients from the Mayo...
ROTTERDAM (the Netherlands), SAN DIEGO (US), April 22, 2021: SkylineDx and Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announce the signing of a new partnership agreement which targets...
ROTTERDAM (the Netherlands), SAN DIEGO (US), March 23, 2021: SkylineDx received the first Merlin Assay clinical test requests and therefore reported initial gross sales ahead of the commercial launch at the World Congress...
ROTTERDAM (The Netherlands) and SAN DIEGO (US), February 23, 2021: today, SkylineDx announces to have signed a license agreement with Oncode Institute and Utrecht Holdings on a shared patent covering the innovative algorithm...
ROTTERDAM (the Netherlands) and SAN DIEGO (US), February 18, 2021: today, SkylineDx announced that it received the esteemed ISO 13485:2016 Quality Management System certificate from notified body BSI Netherlands, after their successful audit...
ROTTERDAM (the Netherlands) and SAN DIEGO (US), February 15, 2021: today, SkylineDx announced a research collaboration with an academic hospital and a Dutch cancer registry to investigate patients with early-stage melanoma (skin cancer)...
